Home » Clinical Trials » Search Clinical Trials
Therapeutic Areas: Oncology | Dermatology/Plastic Surgery
Clinical Trials: Malignant Melanoma
A listing of clinical trials currently looking for volunteers to enroll in Malignant Melanoma studies. Click on the closest city to find more detailed information on a research study in your area.
California
Los Angeles :
A Study of DEDN6526A in Patients With Metastatic or Unresectable Melanoma
Los Angeles :
A Study of RO5185426 And GDC-0973 in Patients With BRAF-Mutation Positive Metastatic Melanoma
Los Angeles :
A Study of Vemurafenib in Metastatic Melanoma Patients With Brain Metastases
San Francisco :
A Study of RO5185426 And GDC-0973 in Patients With BRAF-Mutation Positive Metastatic Melanoma
Santa Monica :
Study Of Zelboraf (Vemurafenib) in Patients With Locally-Advanced, Unresectable, Stage IIIc Or Metastatic Melanoma and Activating Exon 15 BRAF Mutations Other Than V600E
Colorado
Aurora :
A Study of RO5185426 And GDC-0973 in Patients With BRAF-Mutation Positive Metastatic Melanoma
Aurora :
A Study of Vemurafenib in Metastatic Melanoma Patients With Brain Metastases
Connecticut
New Haven : Yale University School Of Medicine
Dose-escalation Study of Combination BMS-936558 (MDX-1106) and Ipilimumab in Subjects With Unresectable Stage III or Stage IV Malignant Melanoma
New Haven : Yale University School of Medicine, Section of Med Onc.
Safety, Tolerability and Efficacy Study of the Monoclonal Antibody, CT-011, in Patients With Metastatic Melanoma
Florida
Miami Beach : Mount Sinai Medical Center
A Study of Intratumoral CAVATAK in Patients With Stage IIIc and Stage IV Malignant Melanoma
Tampa : Moffitt Cancer Center Cutaneous Oncology Department
Safety, Tolerability and Efficacy Study of the Monoclonal Antibody, CT-011, in Patients With Metastatic Melanoma
Illinois
Chicago :
A Study of RO5185426 And GDC-0973 in Patients With BRAF-Mutation Positive Metastatic Melanoma
Chicago : Northwestern Memorial Hospital
Safety, Tolerability and Efficacy Study of the Monoclonal Antibody, CT-011, in Patients With Metastatic Melanoma
Chicago : The University of Chicago
Safety, Tolerability and Efficacy Study of the Monoclonal Antibody, CT-011, in Patients With Metastatic Melanoma
Niles : Oncology Specialists, SC
A Study of Intratumoral CAVATAK in Patients With Stage IIIc and Stage IV Malignant Melanoma
Park Ridge :
Study Of Zelboraf (Vemurafenib) in Patients With Locally-Advanced, Unresectable, Stage IIIc Or Metastatic Melanoma and Activating Exon 15 BRAF Mutations Other Than V600E
Massachusetts
Boston :
A Study of Vemurafenib in Metastatic Melanoma Patients With Brain Metastases
Boston : Dana-Farber Cancer Institute
Panobinostat (LBH589) in Patients With Metastatic Melanoma
Boston : Beth Israel Deaconess Medical Center
Safety, Tolerability and Efficacy Study of the Monoclonal Antibody, CT-011, in Patients With Metastatic Melanoma
Boston : Dana Farber Cancer Institute
Safety, Tolerability and Efficacy Study of the Monoclonal Antibody, CT-011, in Patients With Metastatic Melanoma
Boston : Mass General Hospital
Safety, Tolerability and Efficacy Study of the Monoclonal Antibody, CT-011, in Patients With Metastatic Melanoma
Michigan
Detroit :
A Study of Vemurafenib in Metastatic Melanoma Patients With Brain Metastases
Missouri
St. Louis :
A Study of Vemurafenib in Metastatic Melanoma Patients With Brain Metastases
New Hampshire
Lebanon :
A Study of the Effect of Food on the Pharmacokinetics of Single Dose RO5185426 And the Safety And Efficacy of Continuous Administration in Patients With BRAF V600E Mutation-Positive Metastatic Melanoma
Lebanon, : Dartmouth Hitchcock Medical Center
Safety, Tolerability and Efficacy Study of the Monoclonal Antibody, CT-011, in Patients With Metastatic Melanoma
New York
New York :
A Study of RO5185426 And GDC-0973 in Patients With BRAF-Mutation Positive Metastatic Melanoma
New York : Memorial Sloan Kettering Cancer Center
Dose-escalation Study of Combination BMS-936558 (MDX-1106) and Ipilimumab in Subjects With Unresectable Stage III or Stage IV Malignant Melanoma
New York : Memorial Sloan Kettering Cancer Center
Safety, Tolerability and Efficacy Study of the Monoclonal Antibody, CT-011, in Patients With Metastatic Melanoma
New York : Ruttenberg Cancer Clinic - The Mount Sinai Hospital
Safety, Tolerability and Efficacy Study of the Monoclonal Antibody, CT-011, in Patients With Metastatic Melanoma
Oregon
Portland : Providence Cancer Center
Safety, Tolerability and Efficacy Study of the Monoclonal Antibody, CT-011, in Patients With Metastatic Melanoma
Pennsylvania
Philadelphia : University of Pennsylvania
Safety, Tolerability and Efficacy Study of the Monoclonal Antibody, CT-011, in Patients With Metastatic Melanoma
Pittsburgh : University of Pittsburgh Medical Center
Safety, Tolerability and Efficacy Study of the Monoclonal Antibody, CT-011, in Patients With Metastatic Melanoma
South Carolina
Charleston :
A Study of the Effect of Food on the Pharmacokinetics of Single Dose RO5185426 And the Safety And Efficacy of Continuous Administration in Patients With BRAF V600E Mutation-Positive Metastatic Melanoma
Tennessee
Memphis : St. Jude Children's Research Hospital
Phase II Study Incorporating Pegylated Interferon In the Treatment For Children With High-Risk Melanoma
Nashville :
A Study of RO5185426 And GDC-0973 in Patients With BRAF-Mutation Positive Metastatic Melanoma
Nashville : Vanderbilt University Medical Center
Safety, Tolerability and Efficacy Study of the Monoclonal Antibody, CT-011, in Patients With Metastatic Melanoma
Texas
Houston : S. R. Burzynski Clinic
Phase II Study Of Antineoplatons A10 And AS2-1 In Patients With Malignant Melenoma
View More »
Dallas : Mary Crowley Cancer Research Centers
A Study of Intratumoral CAVATAK in Patients With Stage IIIc and Stage IV Malignant Melanoma
Dallas : Baylor Univesity Medical Center
Safety, Tolerability and Efficacy Study of the Monoclonal Antibody, CT-011, in Patients With Metastatic Melanoma
Houston : The Children's Cancer Hospital at UT M.D. Anderson Cancer Center
Phase II Study Incorporating Pegylated Interferon In the Treatment For Children With High-Risk Melanoma
Houston : University of Texas MD Anderson Cancer Center
Safety and Efficacy Study of INGN 241 Gene Therapy in Patients With In Transit Melanoma
Utah
Salt Lake City : Huntsman Cancer Institute
A Study of Intratumoral CAVATAK in Patients With Stage IIIc and Stage IV Malignant Melanoma
Virginia
Charlottesville : University of Virginia Health System / Human Immune Therapy Center
Safety, Tolerability and Efficacy Study of the Monoclonal Antibody, CT-011, in Patients With Metastatic Melanoma
Washington
Seattle :
A Study of Vemurafenib in Metastatic Melanoma Patients With Brain Metastases
Argentina
Buenos Aires :
A Study of RO5185426 in Patients With Metastatic Melanoma
Australia
Greenslopes :
A Study of RO5185426 in Patients With Metastatic Melanoma
Melbourne :
A Study of RO5185426 And GDC-0973 in Patients With BRAF-Mutation Positive Metastatic Melanoma
Melbourne :
A Study of RO5185426 in Patients With Metastatic Melanoma
Melbourne :
A Study of Vemurafenib in Metastatic Melanoma Patients With Brain Metastases
North Sydney :
A Study of RO5185426 in Patients With Metastatic Melanoma
View More »
Townsville :
A Study of RO5185426 in Patients With Metastatic Melanoma
Waratah :
A Study of RO5185426 in Patients With Metastatic Melanoma
Westmead :
A Study of RO5185426 in Patients With Metastatic Melanoma
Wodonga, Vic :
A Study of RO5185426 in Patients With Metastatic Melanoma
Woolloongabba :
A Study of RO5185426 in Patients With Metastatic Melanoma
Austria
Feldkirch :
A Study of RO5185426 in Patients With Metastatic Melanoma
Graz :
A Study of RO5185426 in Patients With Metastatic Melanoma
Graz : Universitätsklinik Graz
Intratumoral Application of L19IL2 in Patients With Malignant Melanoma
Innsbruck :
A Study of RO5185426 in Patients With Metastatic Melanoma
Linz :
A Study of RO5185426 in Patients With Metastatic Melanoma
View More »
Salzburg :
A Study of RO5185426 in Patients With Metastatic Melanoma
St. Pölten :
A Study of RO5185426 in Patients With Metastatic Melanoma
Wien :
A Study of RO5185426 in Patients With Metastatic Melanoma
Belgium
Bruxelles :
A Study of RO5185426 in Patients With Metastatic Melanoma
Wilrijk :
A Study of RO5185426 in Patients With Metastatic Melanoma
Brazil
Sao Paulo :
A Study of RO5185426 in Patients With Metastatic Melanoma
Bulgaria
Plovdiv :
A Study of RO5185426 in Patients With Metastatic Melanoma
Sofia :
A Study of RO5185426 in Patients With Metastatic Melanoma
Canada
Edmonton :
A Study of RO5185426 in Patients With Metastatic Melanoma
Halifax :
A Study of RO5185426 in Patients With Metastatic Melanoma
Hamilton :
A Study of RO5185426 in Patients With Metastatic Melanoma
London :
A Study of RO5185426 in Patients With Metastatic Melanoma
Montreal :
A Study of RO5185426 in Patients With Metastatic Melanoma
View More »
Ottawa :
A Study of RO5185426 in Patients With Metastatic Melanoma
Quebec City :
A Study of RO5185426 in Patients With Metastatic Melanoma
Toronto :
A Study of RO5185426 in Patients With Metastatic Melanoma
Toronto :
A Study of Vemurafenib in Metastatic Melanoma Patients With Brain Metastases
Vancouver :
A Study of RO5185426 in Patients With Metastatic Melanoma
Winnipeg :
A Study of RO5185426 in Patients With Metastatic Melanoma
Colombia
Bogota :
A Study of RO5185426 in Patients With Metastatic Melanoma
Cali :
A Study of RO5185426 in Patients With Metastatic Melanoma
Croatia
Zagreb :
A Study of RO5185426 in Patients With Metastatic Melanoma
Czech Republic
Brno :
A Study of RO5185426 in Patients With Metastatic Melanoma
Olomouc :
A Study of RO5185426 in Patients With Metastatic Melanoma
Ostrava :
A Study of RO5185426 in Patients With Metastatic Melanoma
Praha :
A Study of RO5185426 in Patients With Metastatic Melanoma
Estonia
Tallin :
A Study of RO5185426 in Patients With Metastatic Melanoma
Tallinn :
A Study of RO5185426 in Patients With Metastatic Melanoma
Tartu :
A Study of RO5185426 in Patients With Metastatic Melanoma
Finland
Helsinki :
A Study of RO5185426 in Patients With Metastatic Melanoma
France
Paris :
A Study of Vemurafenib in Metastatic Melanoma Patients With Brain Metastases
Germany
Essen :
A Study of Vemurafenib in Metastatic Melanoma Patients With Brain Metastases
Freiburg : University Medical Center Freiburg, Department of Dermatology
Quality of Life and Psychological Well-being in Patients With Malignant Melanoma
Hannover : Medizinischen Hochschule Hannover
Intratumoral Application of L19IL2 in Patients With Malignant Melanoma
Jena :
A Study of RO5185426 in Comparison With Dacarbazine in Previously Untreated Patients With Metastatic Melanoma (BRIM 3)
Kiel :
A Study of Vemurafenib in Metastatic Melanoma Patients With Brain Metastases
View More »
Köln : University Medical Center Collogne, Department of Dermatology
Quality of Life and Psychological Well-being in Patients With Malignant Melanoma
Tübingen :
A Study of Vemurafenib in Metastatic Melanoma Patients With Brain Metastases
Tuebingen : University Hospital
Intratumoral Application of L19IL2 in Patients With Malignant Melanoma
Greece
Athens :
A Study of RO5185426 in Patients With Metastatic Melanoma
Hungary
Budapest :
A Study of RO5185426 in Patients With Metastatic Melanoma
Debrecen :
A Study of RO5185426 in Patients With Metastatic Melanoma
Pecs :
A Study of RO5185426 in Patients With Metastatic Melanoma
Szeged :
A Study of RO5185426 in Patients With Metastatic Melanoma
Israel
Jerusalem : Oncology institute, Shaare Zedek Medical Center
IVIG in the Treatment of Metastatic Cancers of the Prostate, Colon and Melanoma
Jerusalem : Hadassah Medical Center
Safety, Tolerability and Efficacy Study of the Monoclonal Antibody, CT-011, in Patients With Metastatic Melanoma
Tel Hashomer : Ella Institute, Oncology institute, Sheba Medical Center
IVIG in the Treatment of Metastatic Cancers of the Prostate, Colon and Melanoma
Tel Hashomer : Oncology Institute, Sheba Medical Center
IVIG in the Treatment of Metastatic Cancers of the Prostate, Colon and Melanoma
Tel Hashomer : Chaim Sheba Medical Center
Safety, Tolerability and Efficacy Study of the Monoclonal Antibody, CT-011, in Patients With Metastatic Melanoma
Italy
Bari :
A Study of RO5185426 in Patients With Metastatic Melanoma
Bergamo :
A Study of RO5185426 in Patients With Metastatic Melanoma
Genova :
A Study of RO5185426 in Patients With Metastatic Melanoma
Meldola :
A Study of RO5185426 in Patients With Metastatic Melanoma
Milano :
A Study of Avastin (Bevacizumab) in Combination With Dacarbazine in Patients With Unresectable/Metastatic Melanoma.
View More »
Milano :
A Study of RO5185426 in Patients With Metastatic Melanoma
Napoli :
A Study of RO5185426 in Patients With Metastatic Melanoma
Padova :
A Study of RO5185426 in Patients With Metastatic Melanoma
Pisa :
A Study of RO5185426 in Patients With Metastatic Melanoma
Roma :
A Study of RO5185426 in Patients With Metastatic Melanoma
Siena :
A Study of RO5185426 in Patients With Metastatic Melanoma
Siena :
A Study of Vemurafenib in Metastatic Melanoma Patients With Brain Metastases
Udine :
A Study of RO5185426 in Patients With Metastatic Melanoma
Korea, Republic of
Seoul :
A Study of RO5185426 in Patients With Metastatic Melanoma
Latvia
Daugavpils :
A Study of RO5185426 in Patients With Metastatic Melanoma
Riga :
A Study of RO5185426 in Patients With Metastatic Melanoma
Lithuania
Klaipeda :
A Study of RO5185426 in Patients With Metastatic Melanoma
Vilnius :
A Study of RO5185426 in Patients With Metastatic Melanoma
Macedonia, The Former Yugoslav Republic of
Skopje :
A Study of RO5185426 in Patients With Metastatic Melanoma
Mexico
Mexico City :
A Study of RO5185426 in Patients With Metastatic Melanoma
Netherlands
Amsterdam :
A Study of RO5185426 in Patients With Metastatic Melanoma
Breda :
A Study of RO5185426 in Patients With Metastatic Melanoma
Nijmegen :
A Study of RO5185426 in Patients With Metastatic Melanoma
Rotterdam :
A Study of RO5185426 in Patients With Metastatic Melanoma
Norway
Bergen :
A Study of RO5185426 in Patients With Metastatic Melanoma
Oslo :
A Study of RO5185426 in Patients With Metastatic Melanoma
Poland
Krakow :
A Study of RO5185426 in Patients With Metastatic Melanoma
Olsztyn :
A Study of RO5185426 in Patients With Metastatic Melanoma
Portugal
Lisboa :
A Study of RO5185426 in Patients With Metastatic Melanoma
Porto :
A Study of RO5185426 in Patients With Metastatic Melanoma
Russian Federation
Krasnodar :
A Study of RO5185426 in Patients With Metastatic Melanoma
Moscow :
A Study of RO5185426 in Patients With Metastatic Melanoma
St Petersburg :
A Study of RO5185426 in Patients With Metastatic Melanoma
Stavropol :
A Study of RO5185426 in Patients With Metastatic Melanoma
UFA :
A Study of RO5185426 in Patients With Metastatic Melanoma
Slovakia
Bratislava :
A Study of RO5185426 in Patients With Metastatic Melanoma
Poprad :
A Study of RO5185426 in Patients With Metastatic Melanoma
Slovenia
Ljubljana :
A Study of RO5185426 in Patients With Metastatic Melanoma
Spain
Barcelona :
A Study of RO5185426 in Patients With Metastatic Melanoma
Barcelona :
A Study of Vemurafenib in Metastatic Melanoma Patients With Brain Metastases
Cordoba :
A Study of RO5185426 in Patients With Metastatic Melanoma
Granada :
A Study of RO5185426 in Patients With Metastatic Melanoma
La Coruna :
A Study of RO5185426 in Patients With Metastatic Melanoma
View More »
La Laguna (tenerife) :
A Study of RO5185426 in Patients With Metastatic Melanoma
Las Palmas de Gran Canaria :
A Study of RO5185426 in Patients With Metastatic Melanoma
Madrid :
A Study of RO5185426 in Patients With Metastatic Melanoma
Malaga :
A Study of RO5185426 in Patients With Metastatic Melanoma
Málaga :
A Study of RO5185426 in Patients With Metastatic Melanoma
Palma de Mallorca :
A Study of RO5185426 in Patients With Metastatic Melanoma
Pamplona :
A Study of RO5185426 in Patients With Metastatic Melanoma
Santander :
A Study of RO5185426 in Patients With Metastatic Melanoma
Sevilla :
A Study of RO5185426 in Patients With Metastatic Melanoma
Valencia :
A Study of RO5185426 in Patients With Metastatic Melanoma
Zaragoza :
A Study of RO5185426 in Patients With Metastatic Melanoma
Sweden
Lund : Lunds Universitetssjukhus
SentoClone® Compared to Reference Treatment in Advanced Malignant Melanoma
Stockholm : Södersjukhuset
SentoClone® Compared to Reference Treatment in Advanced Malignant Melanoma
Stockholm : Karolinska Sjukhuset
SentoClone® Compared to Reference Treatment in Advanced Malignant Melanoma
Umeå : Norrlands Universitetssjukhus
SentoClone® Compared to Reference Treatment in Advanced Malignant Melanoma
Switzerland
Chur :
A Study of RO5185426 in Patients With Metastatic Melanoma
Turkey
Gaziantep :
A Study of RO5185426 in Patients With Metastatic Melanoma
United Kingdom
Birmingham : Queen Elizabeth Hospital
Study to Assess the Tolerability of a Bispecific Targeted Biologic IMCgp100 in Malignant Melanoma
Cambridge :
A Study of RO5185426 in Patients With Metastatic Melanoma
Cambridge : Addenbrooke's Hospital
Study to Assess the Tolerability of a Bispecific Targeted Biologic IMCgp100 in Malignant Melanoma
Glasgow :
A Study of RO5185426 in Patients With Metastatic Melanoma
Glasgow : The Beatson Institute
Study to Assess the Tolerability of a Bispecific Targeted Biologic IMCgp100 in Malignant Melanoma
View More »
Leeds :
A Study of RO5185426 in Patients With Metastatic Melanoma
Leeds : St James' Institute of Oncology
Study of a DNA Immunotherapy to Treat Melanoma
Leeds : St James Hospital
Study to Assess the Tolerability of a Bispecific Targeted Biologic IMCgp100 in Malignant Melanoma
London :
A Study of RO5185426 in Patients With Metastatic Melanoma
Manchester :
A Study of RO5185426 in Patients With Metastatic Melanoma
Manchester : Christie Hospital
Study of a DNA Immunotherapy to Treat Melanoma
Newcastle Upon Tyne :
A Study of RO5185426 in Patients With Metastatic Melanoma
Newcastle-upon-Tyne : Northern Centre for Cancer Care, Freeman Hospital
Study of a DNA Immunotherapy to Treat Melanoma
Northwood :
A Study of RO5185426 in Patients With Metastatic Melanoma
Northwood :
A Study of Vemurafenib in Metastatic Melanoma Patients With Brain Metastases
Nottingham :
A Study of RO5185426 in Patients With Metastatic Melanoma
Nottingham : Department of Clinical Oncology, City Hospital
Study of a DNA Immunotherapy to Treat Melanoma
Oxford :
A Study of RO5185426 in Patients With Metastatic Melanoma
Oxford : NIHR Biomedical Research Centre
Study to Assess the Tolerability of a Bispecific Targeted Biologic IMCgp100 in Malignant Melanoma
Southampton : Department of Medical Oncology, Southampton General Hospital
Study of a DNA Immunotherapy to Treat Melanoma
Swansea :
A Study of RO5185426 in Patients With Metastatic Melanoma
